Heart attack

April 22, 2019

Molecular therapy for cardiac dysfunction: Canagliflozin (trade name: Invokana), a medication used to treat hyperglycemia, decreases Mir-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function, via upregulation of its target gene, 22/April/2018, 10.31 pm

Molecular therapy for cardiac dysfunction: Canagliflozin (trade name: Invokana), a medication used to treat hyperglycemia, decreases Mir-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function, via upregulation of its target gene, 22/April/2018, 10.31 pm https://genomediscovery.org/wp-content/uploads/2019/04/Canagliflozin-attenuates-pathogenesis-associated-with-cardiac-hypertrophy-and-fibrosis-through-down-regulation-of-MiR29-and-up-regulation-of-GSK3B-ICAT.CTNNBIP1-and-GLIS2-4.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/Canagliflozin-attenuates-pathogenesis-associated-with-cardiac-hypertrophy-and-fibrosis-through-down-regulation-of-MiR29-and-up-regulation-of-GSK3B-ICAT.CTNNBIP1-and-GLIS2-4.jpg April 22, 2019 April 22, 2019

Introduction: What they say: A recent study from the Institute of Pharmacology and Toxicology, Technical University Munich (TUM), 80802, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich…

April 21, 2019

Intracardiac injection of Cyclic helix-B peptide (CHBP) attenuates pathogenesis-associated with Myocardial infarction: Cyclic helix-B peptide (CHBP) decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target gene, 22/April/2019, 12.07 am

Intracardiac injection of Cyclic helix-B peptide (CHBP) attenuates pathogenesis-associated with Myocardial infarction: Cyclic helix-B peptide (CHBP) decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target gene, 22/April/2019, 12.07 am https://genomediscovery.org/wp-content/uploads/2019/04/Intracardiac.epicardial-injection-of-Cyclic-helix-B-peptide-CHBP-enhances-cardiac-contractility-and-attenuates-pathogenesis-associated-with-myocardial-infarction2.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/Intracardiac.epicardial-injection-of-Cyclic-helix-B-peptide-CHBP-enhances-cardiac-contractility-and-attenuates-pathogenesis-associated-with-myocardial-infarction2.jpg April 21, 2019 April 21, 2019

Introduction: What they say: A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston,…

April 18, 2019

Intracardiac injection of Cyclic helix B peptide (CHBP) promotes heart regeneration and repair: Intracardiac injection of Cyclic helix B peptide (CHBP) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 18/April/2019, 10.55 pm

Intracardiac injection of Cyclic helix B peptide (CHBP) promotes heart regeneration and repair: Intracardiac injection of Cyclic helix B peptide (CHBP) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 18/April/2019, 10.55 pm https://genomediscovery.org/wp-content/uploads/2019/04/Intracardiac.epicardial-injection-of-Cyclin-helix-B-peptide-CHBP-increases-cardiomyocyte-proliferation.regeneration-enhances-cardiac.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/Intracardiac.epicardial-injection-of-Cyclin-helix-B-peptide-CHBP-increases-cardiomyocyte-proliferation.regeneration-enhances-cardiac.jpg2_.jpg April 18, 2019 April 18, 2019

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and…

April 18, 2019

Intracardiac injection of Synthetic PreImplantation Factor (sPIF) promotes heart regeneration and repair: Intracardiac injection of Synthetic PreImplantation Factor (sPIF) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 18/April/2019, 8.01 am

Intracardiac injection of Synthetic PreImplantation Factor (sPIF) promotes heart regeneration and repair: Intracardiac injection of Synthetic PreImplantation Factor (sPIF) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 18/April/2019, 8.01 am https://genomediscovery.org/wp-content/uploads/2019/04/Intracardiac.epicardial-injection-of-Synthetic-PreImplantation-Factor-sPIF-protects-against-myocardial-dysfunction.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/Intracardiac.epicardial-injection-of-Synthetic-PreImplantation-Factor-sPIF-protects-against-myocardial-dysfunction.jpg2_.jpg April 18, 2019 April 18, 2019

April 18, 2019

The anti-diabetic drug Canagliflozin protects against Myocardial Infarction and its associated complications: Canagliflozin (brand name: Invokana and Sulisent), a sodium -glucose co-transporter-2 inhibitor used in the treatment of TIIDM, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 18/April/2019, 6.50am

The anti-diabetic drug Canagliflozin protects against Myocardial Infarction and its associated complications: Canagliflozin (brand name: Invokana and Sulisent), a sodium -glucose co-transporter-2 inhibitor used in the treatment of TIIDM, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 18/April/2019, 6.50am https://genomediscovery.org/wp-content/uploads/2019/04/Canagliflozin-protects-against-pathogenesis-associated-with-Myocardial-infarction-and-cardiac-ageing-through-up-regulation-of-PNUTS.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/Canagliflozin-protects-against-pathogenesis-associated-with-Myocardial-infarction-and-cardiac-ageing-through-up-regulation-of-PNUTS.jpg April 18, 2019 April 18, 2019

What they say: A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March 2013 issue of of the journal Nature (impact…

April 9, 2019

Intracardiac injection of Cyclin helix B peptide (CHBP) protects against Myocardial infarction: Cyclin helix B peptide (CHBP) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 9/April/2019, 11.56 pm

Intracardiac injection of Cyclin helix B peptide (CHBP) protects against Myocardial infarction: Cyclin helix B peptide (CHBP) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 9/April/2019, 11.56 pm https://genomediscovery.org/wp-content/uploads/2019/04/Intracardiac.Epicardial-injection-of-Cyclic-helix-B-peptide-CHBP-improves-myocardium-function-after-myocardial-infarction-and-protects-against-cardiac-ageing-through-up-regulation-of-PNUTS.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/04/Intracardiac.Epicardial-injection-of-Cyclic-helix-B-peptide-CHBP-improves-myocardium-function-after-myocardial-infarction-and-protects-against-cardiac-ageing-through-up-regulation-of-PNUTS.jpg April 9, 2019 April 9, 2019

Popular Post